Showing results (441-450 of 1,750) with videos related to
Sort By:
Pageof 175
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2026
Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term RemissionOlivia Wilkins, Alex Marki, Kellie A Gardner, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 13, 2026
IGF2BP3-Mediated m6A Modification of OLR1 mRNA Promotes Immune Evasion in CRC via the PI3K/AKT/mTOR PathwayWei ChenJournal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2000
Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptideA Ladányi, M I Nishimura, S A Rosenberg, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2000
Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancerM deMagalhaes-Silverman, A Donnenberg, B Lembersky, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 5, 1999
Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I studyF Di Filippo, C R Rossi, M Vaglini, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 26, 1999
Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigenA Hombach, C Heuser, R Sircar, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 26, 1999
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor modelH L Kaufman, J B Rao, K R Irvine, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 26, 1999
Bispecific antibodies in cancer therapy, from the laboratory to the clinicR Koelemij, P J Kuppen, C J van de Velde, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 26, 1999
Phase II clinical study on the effects of recombinant human interleukin-3 on thrombocytopenia after chemotherapy for advanced ovarian cancer. SDZ ILE 964 [IL-3] Study GroupK Yamamoto, A Yajima, Y Terashima, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 8, 2001
MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine designG ZengPageof 175